.@llovet_m, of @mountsinailiver, previews the long-term OS results of the phase 3 LEAP-012 study with lenvatinib plus pembrolizumab vs dual placebo with transarterial chemoembolization in unresectable non-metastatic hepatocellular carcinoma @myESMO #ESMO26 #oncology